DBIBB is a specific non-lipid agonist of the lysophosphatidic acid (LPA2) type 2 G protein-coupled receptor; it alleviates gastrointestinal radiation syndrome, enhances intestinal crypt survival and enterocyte proliferation, reduces apoptosis, and is a candidate therapeutic agent for mitigating acute radiation syndrome in the hematopoietic and gastrointestinal systems caused by high-dose γ-irradiation.